 Life Science Investor Mandates (Mar. 5 - Mar. 11) |
| |
|
Seeking Early Stage Oncology Opportunities
|
Seeking Life Science Investments Globally
|
|
Seeking to In-License Clinical Stage Therapeutics in Neurology, Hepatology, and Gastroenterology
|
The Magnificent Seven-Fundraising Challenges Facing Life Science Entrepreneurs
|
Northeast Life Science Innovation: Diverse Fields of Assets and Investors
|
|
[Video] Biotech Angel Groups Panel at RESI 4
|
|
|
|
Entrepreneurs in the life science space face a myriad of challenges on the commercialization journey including fundraising. While the current open IPO window has certainly shed positive light on the sector, early stage life science companies are still facing an uphill climb when it comes to fundraising. There is simply a limited amount of capital available to fund a burgeoning number of products, ideas, and solutions that can no longer be supported by government or academic sources. However, the supply and demand of capital is not the only hindrance to an early stage life science company; below are seven fundraising pitfalls that we hear about on a daily basis in our dialogues with investors and entrepreneurs.
1.Contributing to "White Noise"
An investor's inbox is often bombarded with messages describing the latest and greatest opportunities; however, more often than not, these opportunities are outside of that investor's wheelhouse. You need to match your company to an investor's current mandate. There are simply not enough hours in the day for an investor to read, let alone respond to, all of these messages, and as a result, many go unnoticed or do not receive an adequate review. While there are those investors who do not specify their investment interests, fundraisers in the entrepreneurial community can remedy this problem by taking the time to properly research and qualify the investors to whom they are reaching out. Make sure when you go after an investor you know it is a fit for your company's sector and stage of development...
|
 |
 |
|
|
By Lucy Parkinson, Senior Research Manager, LSN
Two weeks ago, we took a dive into early stage life science assets in the Southwest region of the U.S. Today, we'll take a look at what's happening closer to our home , here in the global life science hub of the Northeast.
Using the LSN Company Platform, we are able to observe the wealth of innovation occurring in this region. We analyzed a sample of biotech and medtech innovators across nine Northeastern states: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. This sample drew from the pipelines of almost 400 life science companies, and included 1596 biotech assets in a range of developmental phases, from Preclinical through Phase III trials, as well as 154 medtech products in development. For 1435 of the biotech assets, we are able to track the primary indication area targeted by the product, as is shown in Figure 1. As in the Southwest, we saw significant pipelines in cancer, diseases of the nervous system , and infectious and parasitic diseases. With such a large sample, even less crowded indication fields such as blood and immune diseases and mental and behavioral disorders possess a significant number of pipeline assets...
|
|
 |
|
By Nono Hu, Senior Manager, Branding & Messaging, LSN
 If you are in the biotech arena looking for capital allocations from angel investors, this recap video is for you. The RESI 4 Biotech Angel Groups Panel features five investors from life science angel networks throughout the USA. In this panel, angels explained how they assess early-stage biotech opportunities and discussed the following topics:- What attracts you to the biotech space as an angel investor?
- What are the headwinds that you see when you look at biotech companies?
- What's the state of optimism regarding mergers and acquisition activity in the next 1-2 years?
- What do you look for in a biotech company that attracts you?
- How do you assess the potential that is locked in biotech companies before they generate revenue?
|
| | RESI 4 Biotech Angel Groups Panel |
|
|
|
